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Background: A wide range of novel psychoactive substances (NPSs) are regularly
searched and discussed online by e-psychonauts. Among NPSs, the range of
prescription/non-prescription opioids (fentanyl and non-fentanyl analogs) and herbal
derivatives currently represents a challenge for governments and clinicians.
Methods: Using a web crawler (i.e., NPS.Finder R©), the present study aimed at assessing
psychonaut fora/platforms to better understand the online situation regarding opioids.
Results: The open-web crawling/navigating software identified some 426 opioids,
including 234 fentanyl analogs. Of these, 176 substances (162 were very potent
fentanyls, including two ohmefentanyl and seven carfentanyl analogs) were not listed
in either international or European NPS databases.
Conclusion: A web crawling approach helped in identifying a large number, indeed
higher than that listed by European/international agencies, of unknown opioids likely
to possess a significant misuse potential. Most of these novel/emerging substances
are still relatively unknown. This is a reason of concern; each of these analogs
potentially presents with different toxicodynamic profiles, and there is a lack of docking,
preclinical, and clinical observations. Strengthening multidisciplinary collaboration
between clinicians and bioinformatics may prove useful in better assessing public health
risks associated with opioids.
Keywords: psychonauts, novel psychoactive substance, novel synthetic opioids, fentanyl analogs, web crawling,
drug misuse, prescribed drug misuse
INTRODUCTION
Novel psychoactive substances (NPSs) are substances that are not controlled by the United Nations
(UN) 1961 Single Convention on Narcotic Drugs or by Psychotropic Substances Conventions
(United Nations Office on Drugs and Crime [UNODC], 2019a). By definition, “novel” does not
necessarily imply that a drug has been recently developed (Hassan et al., 2017); it may also refer
to substances that have lately become popular and/or more widely available, constituting a reason
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of current or potential public health concern (Schifano et al.,
2015). NPSs are mainly of synthetic origin and comprise different
drug classes (Schifano et al., 2019b). Among them, over the
recent years, there has been an increase in the appearance of
novel synthetic opioids (NSOs) on the recreational drug market
(Zawilska, 2017). NSOs are frequently used with other illegal or
prescribed drugs (Pichini et al., 2018; Pérez-Mañá et al., 2018).
Owing to a range of reasons, the non-medical use of opioids such
as fentanyl analogs and a range of remaining prescription/non-
prescription substances is spreading worldwide (Prekupec et al.,
2017; Lovrecic et al., 2019) and is affecting the entire life span,
from youngsters to the elderly (Huhn et al., 2018; Kelley-Quon
et al., 2019). Opioids are among the most powerful analgesic
drugs, but they are burdened by unwanted adverse effects, in
particular the abuse liability and the respiratory depression,
with the last being the primary cause of death from overdose
(Valentino and Volkow, 2018; Algera et al., 2019; Varga et al.,
2020). Further, the evidence suggests that opioids’ consumption
impacts the in utero neuronal development and induces in
humans long-lasting transgenerational changes in subsequent
generations owing to epigenetic alterations (Gilardi et al., 2018).
For these reasons, worldwide intensive endeavors are directed
from academics, clinicians, and industries toward expanding,
intensifying, and coordinating fundamental, translational, and
clinical research with respect to opioid abuse. To this respect,
there is strong focus at present on the study and development
of abuse-deterrent opioid formulations (Pergolizzi et al., 2018).
Despite the efforts of law enforcement and other agencies
(European Monitoring Centre for Drugs and Drug Addiction
[EMCDDA], 2019; United Nations Office on Drugs and Crime
[UNODC], 2019c), an unknown number of substances are
continuously manufactured, (illicitly) offered for sale, and
inappropriately consumed (Davey et al., 2012; Orsolini et al.,
2017). Some concerns are related as well to the lack of regulation
relating to so-called home-brew opiates (Galanie et al., 2015;
Oye et al., 2015).
Number of Opioids Identified
By April 2019, the EMCDDA European Database on New Drugs
(European Database on New Drugs [EDND], 2019) contained
751 entries, with 51 of them being classified as opioids. By
February 2019, the UNODC listed a total of 892 substances in
their NPS database (Unodc Early Warning Advisory on New
Psychoactive Substances [UNODC EWA NPS], 2019), with 61
being NSOs. It could, however, be argued that the NPS scenario
is much larger than that outlined by those substances that have
been seized and formally identified by the European Union (EU)
and the UN databases. Because the online NPS scenario typically
predicts the real-life NPS market availability (Corazza et al., 2013;
Schifano et al., 2015), identifying what is being discussed online
by web-based NPS enthusiasts (e.g., the “e-psychonauts”) may
well be of interest (Orsolini et al., 2015; Corkery et al., 2017).
Although data about the clinical, pharmacological, and
toxicological characteristics of a number of opioid drugs have
already been made available (Suzuki and El-Haddad, 2017;
Armenian et al., 2018; Baumann et al., 2018; Beardsley and
Zhang, 2018; Tabarra et al., 2019), there is a clear lack of
knowledge relating to the number of novel substances offered
to online/real-life customers (Kacinko and Papsun, 2019), also
owing to the difficulties in detecting them in both interdiction
and clinical settings (Abdulrahim and Bowden-Jones, 2018).
Aims
The aim of the current research was to (a) identify and categorize
the number of opioids collected by the NPS.Finder R© web crawler
from a range of psychonaut, NPS-related, online sources; and (b)
compare the NPS.Finder R© opioid list with related findings from
the UNODC and the EMCDDA.
MATERIALS AND METHODS
Identification of Substances
To facilitate the process of early recognition of the increasing
dissemination of new substances online and the variability
of information sources, a crawling/navigating software (i.e.,
“NPS.Finder R©”) was designed to automatically scan the
open/surface web for new/novel/emerging NPSs (for a thorough
description of web crawling and data cleaning activities, see
Schifano et al., 2019b). This software was designed to map
on a 24/7 basis the large variety of psychoactive substances
mentioned/discussed within a range of popular online
psychonauts websites/fora. NPS.Finder R© was designed de
novo (e.g., it was not designed by the authors; neither was it
adapted from another program) by Damicom, an IT enterprise
based in Rome (Italy), to extract a range of information
regarding NPSs, including chemical and street names; chemical
formula; three-dimensional images; and anecdotally reported
clinical/psychoactive effects. These data were then automatically
stored in an online, restricted-access/password-controlled
database located within firewall protected, highly secure, and
consistently performing servers. First, a number of proper
piloting searches were carried out (see also Schifano et al.,
2019b), and any new website of interest was added to the list,
whose final version is attached as Table 1. Although the language
most typically used in these websites was English, further
languages analyzed by NPS.Finder R© included the following:
Dutch, French, Turkish, Swedish, Spanish, German, Russian,
and Italian. Afterward, a range of specific web scraper/crawler
activities, to extract all accessible posts/entries from November
26, 2017 to May 31, 2019, were carried out. With the help an
ad hoc check control panel, all data were manually and carefully
analyzed by four medically/psychiatrically trained professionals
(e.g., FN, DA, CZ, and LG). In this way, a full assessment and
editing of each NPS.Finder R© data entry were carried out, and the
range of unique opioids here commented was identified. Finally,
using chemical structure identification and published related
data, researchers assigned each molecule to its NPS drug class
(Schifano et al., 2019b).
Classification of Opioid Drugs
The web crawler-identified substances’ denominations were
first searched in Medline/PubMed (PubMed, 2019) and in
Google R©/Google R© Scholar (Google, 2019; Google Scholar, 2019).
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TABLE 1 | NPS.Finder R© websites’ list; search activities carried out on the surface
web only.
N Website name
1 Avalonmagicplants.com
2 Azarius.net
3 Bluelight.org
4 Bluemorphotours.com
5 Cannabis.net
6 Chemeurope.com
7 Committedpsychonaut.tumblr.com
8 Consolidated Index of Controlled Substances
9 Daath.hu/psychonauts
10 Dancesafe.org
11 Deviantart.com/psychonaut-a
12 Druglibrary.org
13 Drugs.tripsit.me
14 Drugs-forum.com
15 Drugs-plaza.com
16 Dutch-headshop.eu
17 Ecstasydata.org
18 Elephantos.com
19 Energycontrol.org
20 http://entheogen-network.com/forums/
21 Erowid.org
22 Eusynth.org
23 https://everything2.com/title/Psychonaut
24 Fungifun.org
25 Hedweb.com
26 Hipforums.com/forum
27 Isomerdesign.com
28 Knehnav.home.xs4all.nl
29 Kratomshop.com
30 Legal-high-inhaltsstoffe.de
31 Mindstates.org
32 Mycotopia.net
33 Natmedtalk.com
34 Npsproject.eu
35 Peyote.com/peyolink.html
36 Psychedelic-library.org
37 Psychonaut.ca
38 Psychonaut.fr
39 Psychonautdocs.com
40 Psychonautwiki.org
41 Psyconauts.tripod.com
42 Reddit.com and drug-related subreddits (e.g.,
Reddit.com/r/Psychonaut/; Reddit.com/r/shroomers/)
43 Shayanashop.com
44 Sjamaan.com
45 Tripzine.com
46 Tryptamind.com
47 Urban75.net
48 Wikipedia List of designer drugs
49 Zamnesia.com
The used terms were “opiates/opioids,” “opioids,” “novel
synthetic opioids,” “fentanyl analogs,” “opioid receptors,” “mu-
opioid receptor,” “delta-opioid receptor,” “kappa-opioid receptor,”
“receptor binding affinity,” and “herbal compounds.” An initial
screening was performed to classify the substances according to
their main description (e.g., fentanyl vs. non-fentanyl analogs).
For this purpose, both the PuCchem (PubChem, 2019) and
ChEMBL (Davies et al., 2015; Gaulton et al., 2017; EMBL-EBI,
2019) were searched; and whenever possible, the International
Union of Pure and Applied Chemistry (IUPAC) name was also
used. For fentanyl analogs, to make sure that the index molecule
was indeed a fentanyl, the IUPAC name proposed by “isomer
design” (PiHKAL, 2019) was here considered. For a handful of
substances, when there were errors in published IUPAC names,
the ChemDraw approach, able to generate chemical names from
structures and/or vice versa, was used (ChemDraw, 2019).
A further screening was performed to compare the
NPS.Finder R© results with those reported by both the EMCDDA
and the UNODC. More precisely, the search was performed on
the following UN databases: International Narcotics Control
Board (INCB) “Yellow List” (International Narcotics Control
Board [INCB], 2019a); the Unodc Early Warning Advisory on
New Psychoactive Substances [UNODC EWA NPS] (2019);
and the fentanyl-related substances INCB report (International
Narcotics Control Board [INCB], 2019a). For European data,
the European Database on New Drugs [EDND] (2019) was
accessed. To understand if an index opioid was currently
being used as a prescribed medication, further screenings were
carried out in the United Kingdom and United States lists
of controlled substances (GOV.UK, 2017; DEA, 2019), and
in the Anatomical Therapeutic Chemical/defined daily dose
(ATC/DDD) list (Chen et al., 2012; WHO Collaborating Centre
[WHOCC], 2016; WHO Collaborating Centre [WHOCC],
2019). The ATC substances were listed according to the ATC
classification by WHO and manually searched in the ATC/DDD
Index (WHO Collaborating Centre [WHOCC], 2019). In the
ATC/DDD Index, most opioids are grouped with the code N02A
(WHO Collaborating Centre [WHOCC], 2016).
RESULTS
Identification and Classification of
Opioid Drugs
After about 18 months of operation, the number of substances
identified by the web crawler activities was 5,922. By the time
of writing, some 4,204 unique NPSs were included in the
database, and 1,718/5,922 (29.01%) remaining substances were
found to be false positives or duplicates. The most common
NPS mentioned in psychonaut fora included the following:
psychedelic phenethylamines (30.1%; CI 95%: 28.7–31.5%);
synthetic cannabimimetics (29.8%; CI 95%: 28.4–31.2%); and
opioids (10.1%; CI 95%: 9.2–11.0%).
The opioids (n = 426) were then divided into two groups:
fentanyl analogs (n = 234; 54.9%; CI 95%: 50.1–59.5%;
Supplementary Table S1) and miscellaneous opioids (n = 192;
45.0%; CI 95%: 40.0–49.8%; Supplementary Tables S2A–C).
The miscellaneous opioids group included the following: (a)
all the prescribing opioids classified in the ATC/DDD Index
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(n = 48; 11.2% of 426; CI 95%: 8.6–14.6%); (b) the non-
fentanyl analog opioids (n = 136; 31.9%; CI 95%: 27.6–36.5%);
and (c) the herbal derivatives (n = 8; 1.8%; CI 95%: 0.9–3.6%)
(Supplementary Tables S2A–C).
Comparison With Novel Psychoactive
Substance-/Opioid-Focused European
and United Nations Databases
Current NPS.Finder R© results were compared with those
pertaining to opioids listed in the EMCDDA and UN databases
(Supplementary Tables 1, 2A–C). Overall, the NPS.Finder R©
detected a larger number of opioids than was in the remaining
databases. The opioids identified by NPS.Finder R© only were
176 chemically different substances. In particular, out of the
234 fentanyl analogs, 162 (69.2% of 234) were listed only in
the NPS.Finder R©; 7 (2.99%; e.g., 4-fluoroisobutyrfentanyl,
acetylfentanyl, acrylfentanyl, butyrylfentanyl, furanylfentanyl,
ocfentanil, and tetrahydrofuranylfentanyl) were listed in all
databases, and the remaining 65 (27.78%) substances were
reported in one or more of the EU or UN databases (i.e.,
INCB Yellow List; INCB “Fentanyl-related substances with no
known legitimate use list”; UNODC EWA NPS; and EDND).
Out of the 136 substances in the non-fentanyl analog opioid
list, 14 (10.29%) were listed only in NPS.Finder R©, and not
in any of the following: INCB Yellow list (updated March
2019), EDND (April 2019), and UNODC EWA NPS (July
2019). The remaining 122 substances were reported both in the
NPS.Finder R© and in at least one of the following: INCB Yellow
list (updated March 2019), EDND (April 2019), or UNODC
EWA NPS (July 2019).
DISCUSSION
To the best of our knowledge, an unprecedented list of opioid
drugs with a possible recreational/misuse potential was generated
by these open web-only crawling software activities, which were
focusing on a range of psychonaut forum entries. For all these
fentanyl/non-fentanyl/miscellaneous drugs, only limited levels
of preclinical/clinical data are typically available (Deluca et al.,
2012; Armenian et al., 2018; Frisoni et al., 2018; Gerace et al.,
2018a; Ventura et al., 2018; European Database on New Drugs
[EDND], 2019; Tabarra et al., 2019; United Nations Office
on Drugs and Crime [UNODC], 2019b). Apart from the vast
range of previously undescribed fentanyl analogs, NPS.Finder R©
identified a further number of “novel” and potent/very potent,
chemically diverse miscellaneous substances. This may suggest
that psychonauts are attracted to a variety of drugs, which
range from research chemicals and their derivatives to more
“traditional” substances, including failed pharmaceuticals or
old patents that have been “rediscovered” and marketed for
their potential use as “recreational” substances (Corkery et al.,
2018). At present, we cannot establish with certainty whether
the opioids here identified are all, or in part, currently
circulating in the community and are available for consumption.
Indeed, the current paper focused on the e-psychonauts’
discussions only; these web-based drug enthusiasts, however,
have been suggested to somehow represent the drug scenarios’
“trend setters” (Schifano et al., 2015, 2019b). Hence, a focus
on web-based drug discussion may well be of interest to
better assess, and possibly predict (Corazza et al., 2013), the
international drug misuse concerns. Ongoing studies from
our group will hopefully better identify the following: a)
which of the e-psychonauts’ substances, including opioids, will
make an entry into the future markets; and b) which is
the time gap, for an index drug, between the start of the
e-psychonauts’ interest and their actual identification on the
international drug scenarios.
Different from both the UNODC and the EMCDDA, which
report in their NPS databases only those substances that
have been both seized from the community and chemically
analyzed, it was unclear from here if the mentioned opioids
have already been synthesized or not. For each mentioned
opioid, however, the unique IUPAC name was here identified
and reported, and those further sources here are considered (e.g.,
PubChem, ChEMBL, ChemDraw, and Isomer Design) confirmed
that the substance was properly chemically characterized.
Hence, one could argue that the rogue producers’ synthesis
of any of the opioids here commented is indeed a real
and distinct possibility (Kata et al., 2018; Financial Crimes
Enforcement Network [FinCHEN], 2019; Pardo et al., 2019;
Whitehouse, 2019).
Present results, highlighting a strong interest by psychonauts
toward opioid drugs, are consistent with previous studies, which
have analyzed the opioids’ debate both in social media settings
(Kalyanam et al., 2017; Kim et al., 2017; Pandrekar et al., 2018; Li
et al., 2019) and on the darknet (Mackey et al., 2018; Tzanetakis,
2018; Cunliffe et al., 2019).
Fentanyl Analogs
Most (e.g., 55%) opioids identified here were fentanyl analogs.
Although present findings do not necessarily confirm in any
possible way these substances’ levels of use, they can still
reflect the attention given by psychonauts to these drugs and
help in explaining aspects of the current “opioid epidemic”
(Kakko et al., 2019; Zhao, 2019). A few fentanyl analogs have
been mentioned in the literature (Suzuki and El-Haddad,
2017; Zawilska, 2017; Misailidi et al., 2018; Lipin´ski et al.,
2019), especially in terms of the acute clinical toxicity issues
relating to their intake (Abdulrahim and Bowden-Jones,
2018). Vulnerable subjects can access online a large number
of these substances (Suzuki and El-Haddad, 2017), without
even being aware of what they are taking exactly (Ciccarone
et al., 2017; Bardwell et al., 2019; McLean et al., 2019; Stein
et al., 2019). Indeed, levels of related clinical toxicological
information are sometimes available only postmortem
(Giorgetti et al., 2017; Concheiro et al., 2018; D’Errico, 2018;
Kraemer et al., 2019).
Apart from a range of some well-known fentanyl-related
substances, two ohmefentanyl and seven carfentanyl analogs
were here identified. It is of interest that the analgesic activity
of ohmefentanyl in mice is 6,300 times more potent than that of
morphine (Xu et al., 1985) and that carfentanyl has been reported
in association with a number of fatalities (Wilcoxon et al., 2018).
Frontiers in Neuroscience | www.frontiersin.org 4 March 2020 | Volume 14 | Article 149
fnins-14-00149 March 16, 2020 Time: 15:33 # 5
Arillotta et al. Novel Opioids and e-Psychonauts’ Scenario
Given the wide range of common and street names available for
each molecule, even small modifications occurring in the fentanyl
family structure can lead to misidentification of the index
drug (Akhondi et al., 2015) and potentially provoke clinically
unexpected effects. It is also possible that some substances here
commented by psychonauts included fentanyl precursors or
metabolites (Wilde et al., 2019). Hence, it is particularly relevant,
for the vast range of fentanyl analogs, to use unique codes such
as those of IUPAC (Gaulton et al., 2017; Hähnke et al., 2018;
PiHKAL, 2019).
Miscellaneous: Non-fentanyl
Compounds, Prescribing Opioids,
Herbals, and Derivatives
The 136 non-fentanyl analog opioids identified in the
NPS.Finder R© database belong to a range of pharmacological
classes, and some 10.2% were not reported by the EU and UN
databases. Several of these substances have been used in the past
for research purposes and/or were never marketed. The present
findings are consistent with the current “top” and “rising” posts
on social networks like Reddit (Reddit, 2019d). Some of these
substances, for example, BDPC/bromadol have already been
described as being some 500 times more potent than morphine
(Reddit, 2019a; Sharma et al., 2019; TripSit Factsheets, 2019a),
whereas others, for example, embutramide, have been associated
with suicidal intent (Lajtai et al., 2016). A range of remaining
substances identified here have received little/no attention
in the literature and include acetoxyketobemidone (e.g., an
alternative to ketobemidone, a prescription analgesic that is
scheduled in different countries; United Nations Office on Drugs
and Crime [UNODC], 1954; Drugs-forum, 2007; Bluelight,
2019a; Reddit, 2019c); 6-methylenedihydrodesoxymorphine/6-
MDDM (e.g., a semi-synthetic derivative of hydromorphone
about 80 times more potent than morphine and associated
with euphoriant effects; Bluelight, 2019b; TripSit Factsheets,
2019b; Reddit, 2019e); isopropyl-U-47700 (identified for the
first time in 2018 and belonging to N-substituted benzamides
and acetamide opioid analgesics, colloquially known as
“U-compounds” or “U-drugs;” Krotulski and Logan, 2018;
Sharma et al., 2019; Yin, 2019); and piperidylthiambutene
(developed in the 1950s and equipotent to morphine;
Adamson and Green, 1950).
NPS.Finder R© identified here virtually all the prescription
opioids listed in the ATC/DDD Index. The psychonauts’ interest
in commenting about these substances may be a reason of
concern, because prescription opioid misuse is a challenging issue
worldwide, especially so in both North America and Europe (van
Amsterdam and van den Brink, 2015; Helmerhorst et al., 2017).
NPS.Finder R© identified as well a range of well-known opioid
herbal compounds, including Papaver somniferum and some
crude opiate extracts (e.g., granulate, tincture, and poppy seed
tea); Mitragyna speciosa/kratom (but not mitragynine and 7-
hydroxymitragynine; Fluyau and Revadigar, 2017; Graziano
et al., 2017; Coe et al., 2019; Corkery et al., 2019); and
Salvia divinorum. Although herkinorin (Ventura et al., 2018)
was not identified in the current database, salvinorin B
ethoxymethyl ether/“Symmetry” (e.g., an unusually potent
synthetic salvinorin compound, potently binding to kappa
opioid receptors; Peet and Baker, 2011; Erowid, 2015; Reddit,
2019b), salvinorin B methoxymethyl (a potent semi-synthetic
derivative of salvinorin A; Baker et al., 2009; Peet and Baker,
2011; Reddit, 2019f; Zjawiony et al., 2019), and salvinorin A
received here the attention of psychonauts. This may be a
cause for concern, because salvinorin products’ psychoactive
effects include perceptual disturbances, psychosis, irritability, and
anxiety (Ventura et al., 2018).
Finally, it is interesting to note that a range of both
endogenous (e.g., amphibian opioid peptides such as
dermorphins and deltorphins) and food-derived (e.g., derivatives
from milk and soya such as soymorphines and β-casomorphins)
opioid peptides, possessing low levels of potency (Teschemacher
et al., 1997; Negri et al., 2000; Ohinata et al., 2007; Liu and
Udenigwe, 2018), were not mentioned in psychonaut fora.
Comparison With European Union and
United Nations Novel Psychoactive
Substance-Related Databases
A total of 426 opioids (e.g., 234 fentanyl analogs and 192
non-fentanyl analogs) were identified. The number of
NPS.Finder R© opioids is indeed higher than that listed by
international agencies like the UNODC and the EMCDDA.
By May 2019, the INCB identified 115 opioids (International
Narcotics Control Board [INCB], 2019a); up to 2019, the
UNODC EWA NPS listed 61 different opioids; by June
2018, the INCB listed 93 fentanyl-related substances with no
known legitimate use (International Narcotics Control Board
[INCB], 2019b); and by April 2019, the EMCDDA reported
51 opioids out a total of 749 EDND substances (European
Database on New Drugs [EDND], 2019). There might be
different reasons behind these inconsistencies. First, both the
UN and EU agencies collect in their databases only those
substances that are detected/seized and properly analyzed
and most importantly reported, respectively, worldwide
or in the European region. Furthermore, the NPS.Finder R©
carried out a range of open web crawling identification
activities focusing on a large range of psychonaut-based,
specialized, multilingual, sources with a specific focus on
new/old psychoactive substances of likely recreational interest.
From this point of view, one could also argue that discussing a
molecule on the web is not, per se, an indication that the index
molecule is being/will be ingested by interested individuals.
This can explain why the opioids common to all lists (e.g.,
the fentanyl analogs 4-fluoroisobutyrfentanyl, acetylfentanyl,
acrylfentanyl, butyrylfentanyl, furanylfentanyl, ocfentanil,
tetrahydrofuranylfentanyl, and the non-fentanyl analogs
AH-7921 and U-47700) are only a small proportion of the total.
Pharmacological and Clinical
Considerations
Fentanyl, fentanyl analogs, and the remaining opioids here
commented present as partial/full agonists, and with different
affinity levels, at the mu, delta, and kappa opioid receptors.
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This may well suggest the existence of a possible vast range
of ill-health consequences associated with these substances
(Stein, 2016). However, a clear understanding of the clinical
toxicity of each compound is at present problematic. In fact,
although the in vitro pKi values/binding affinities, potency, and
efficacy levels for a number of opioids are already available
(World Health Organization [WHO], 2016; Baumann et al.,
2018; World Health Organization [WHO], 2018), these may
not provide enough information about the relative in vivo
potency (Baumann et al., 2018). In fact, there might be
variable effects on G-protein-coupled receptors, which could
potentially give rise to a great diversity of intracellular
consequences following the administration of different analogs
with apparently similar pharmacodynamics (Smith et al.,
2018). Furthermore, as highlighted using a molecular docking
model, some substances are too structurally similar for the
scoring function to distinguish between different analogs (Ellis
et al., 2018, 2019). For some opioids, larger dosages of
naloxone may be required to reverse the opioid toxidrome
than needed in case of a typical heroin overdose (Armenian
et al., 2018; Lovrecic et al., 2019). The greatest levels of
concerns remain related to fentanyl analogs, because of their
harmful potential (Schifano et al., 2019a), the continuous high
incidence of emerging analogs on the markets over the last
years (Schueler, 2017), and the difficulties in identifying them
with analytical chemistry techniques (Gerace et al., 2018b;
Morrow et al., 2019). Conversely, those substances here identified
possessing a full/partial kappa opioid receptor agonist activities
(including salvinorin A and its derivatives; tifluadom; and
pethidine) are likely to be particularly attractive for opioid
and other research chemical consumers prone to a recreational
experimentation associated with complex psychoactive effects
(Coffeen and Pellicer, 2019).
Limitations
NPS.Finder R© crawled only on the open web during the
present phase of its development. Future studies by our
group will be focused on expanding drug searches on less
accessible areas of the web such as the deep web and the
darknet (Orsolini et al., 2017). A qualitative/netnographic
approach (Loi et al., 2017; Wang, 2019) will be needed
as well to better assess the levels of online information
relating to the possible psychonauts’ preference between analogs
and their motivation for use, that is, recreational or self-
medication purposes. As previous studies have highlighted their
importance in NPS-based studies (Deluca et al., 2012), next
NPS.Finder R©-based projects will need to focus as well on further
languages, for example, Chinese, Japanese, and Arabic. Some
consideration needs to be given as well to some opioids not
having been reported by NPS.Finder R©. The present findings,
however, relate only to the psychonauts’ interest, who are
typically debating/discussing/mentioning only those substances
that are considered as “trendy.” Furthermore, it is possible
that owing to fentanyl/non-fentanyl nomenclature issues, there
may be discrepancies between the denomination of substances
resulting from international/EU interdiction data and those
mentioned by psychonauts.
CONCLUSION
The web crawler activities may well possess the potential to
identify a wide range of novel/previously undescribed NPSs,
including opioids. The literature base regarding these substances
is limited in terms of acute and long-term effects, adverse effects,
abuse potential, and manufacturing/distribution in both the
virtual and real markets. It is difficult for health professionals to
keep up to date with the growing number of opioids being made
available. Clinicians are not always aware of the risks relating to
novel psychoactives’ intake, and, at the same time, they are not
typically able to identify a potential NPS user (Simonato et al.,
2013). This may be a reason for concern, especially for emergency
professionals confronting acute, and at times dramatic, clinical
situations that are suspected of being drug related but in which
the standard urine specimen turns out to be negative (Guirguis
et al., 2017). Hence, clinicians should be informed about the range
of opioids, their idiosyncratic drug–drug combinations, and their
medical risks (Orsolini et al., 2015). The availability of new digital
technologies, and the current systematic web crawling activities,
provided here better levels of knowledge about the emerging
number of opioid derivatives. This may help in designing and
developing a range of efficient opioid on−site screening and
detection techniques (Guirguis et al., 2017) and in drafting potent
opioids’ specific treatment and management guidelines.
Raising awareness and education among users, the general
public, and frontline staff and the development of harm reduction
techniques are of paramount importance to tackle the flood of
opioids. The epidemic of opioid overdose is a complex problem
that can only be addressed by concerted and multidisciplinary
efforts. Indeed, in silico, in vitro, and in vivo studies could provide
important findings; furthermore, it is deemed here essential
to monitor the real-life scenarios through drug checking in
interdiction, drug outpatient clinics, and critical care settings.
The provided lists can be useful in prospective and forward-
looking terms. More studies should aim at providing better levels
of misusing drugs’ clinical pharmacological-related knowledge,
so that properly tailored prevention strategies can be drawn up
and made available.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
AUTHOR CONTRIBUTIONS
FS and AV have conceived the idea of the manuscript and
have coordinated the whole project. FN, CZ, DA, and LG have
actually carried out the process of both data collection and
systematization. DA performed the literature searches and the
analysis of data and drafted the manuscript. FS and JC supervised
the writing of the manuscript and contributed to the final version
of the manuscript. FS and EA approved the final content of the
manuscript. JC provided data from the EMCDDA and UNODC
Frontiers in Neuroscience | www.frontiersin.org 6 March 2020 | Volume 14 | Article 149
fnins-14-00149 March 16, 2020 Time: 15:33 # 7
Arillotta et al. Novel Opioids and e-Psychonauts’ Scenario
databases for the purposes of this research. FS, JC, and AG have
provided relevant epidemiological data and have contributed as
well to the drafting of the manuscript itself.
ACKNOWLEDGMENTS
The authors are grateful to Damicom srl, a small enterprise
from Rome (Italy), whose professionals have developed the
NPS.Finder R© web crawler and so generously have allowed here
the testing of its potential.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fnins.
2020.00149/full#supplementary-material
REFERENCES
Abdulrahim, D., and Bowden-Jones, O. (2018). The Misuse of Synthetic Opioids:
Harms and Clinical Management of Fentanyl, Fentanyl Analogues and Other
Novel Synthetic Opioids Information for Clinicians. Available online at: http:
//www.neptune-clinical-guidance.co.uk (accessed August 8, 2019).
Adamson, D. W., and Green, A. F. (1950). A new series of analgesics. Nature
165:122. doi: 10.1038/165122a0
Akhondi, S. A., Muresan, S., Williams, A. J., and Kors, J. A. (2015). Ambiguity
of non-systematic chemical identifiers within and between small-molecule
databases. J. Cheminform. 7:54. doi: 10.1186/s13321-015-0102-6
Algera, M. H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts,
L., et al. (2019). Opioid-induced respiratory depression in humans: a review of
pharmacokinetic-pharmacodynamic modelling of reversal. Br. J. Anaesth. 122,
e168–e179. doi: 10.1016/j.bja.2018.12.023
Armenian, P., Vo, K. T., Barr-Walker, J., and Lynch, K. L. (2018). Fentanyl,
fentanyl analogs and novel synthetic opioids: a comprehensive review.
Neuropharmacology 134, 121–132. doi: 10.1016/j.neuropharm.2017.10.016
Baker, L. E., Panos, J. J., Killinger, B. A., Peet, M. M., Bell, L. M., Haliw, L. A., et al.
(2009). Comparison of the discriminative stimulus effects of salvinorin A and its
derivatives to U69,593 and U50,488 in rats. Psychopharmacology 203, 203–211.
doi: 10.1007/s00213-008-1458-3
Bardwell, G., Boyd, J., Arredondo, J., McNeil, R., and Kerr, T. (2019). Trusting the
source: the potential role of drug dealers in reducing drug-related harms via
drug checking. Drug Alcohol. Depend. 198, 1–6. doi: 10.1016/j.drugalcdep.2019.
01.035
Baumann, M. H., Majumdar, S., Le Rouzic, V., Hunkele, A., Uprety, R., Huang,
X. P., et al. (2018). Pharmacological characterization of novel synthetic opioids
(NSO) found in the recreational drug marketplace. Neuropharmacology 134,
101–107. doi: 10.1016/j.neuropharm.2017.08.016
Beardsley, P. M., and Zhang, Y. (2018). Synthetic opioids. Handb. Exp. Pharmacol.
252, 353–381. doi: 10.1007/164_2018_149
Bluelight, (2019a). Opioids - Big & Dandy Ketobemidone (Ketogan) Thread.
Available online at: https://www.bluelight.org/xf/threads/big-dandy-
ketobemidone-ketogan-thread.69412/ (accessed August 28, 2019).
Bluelight, (2019b). 6-Mddm. Available online at: https://www.bluelight.org/xf/
threads/6-mddm.863982/ (accessed October 9, 2019).
ChemDraw, (2019). Chemical Drawing Software. Available online at: https://www.
perkinelmer.com/it/category/chemdraw (accessed October 9, 2019).
Chen, L., Zeng, W. M., Cai, Y. D., Feng, K. Y., and Chou, K. C. (2012). Predicting
Anatomical therapeutic chemical (ATC) classification of drugs by integrating
chemical-chemical interactions and similarities. PLoS One 7:e35254. doi: 10.
1371/journal.pone.0035254
Ciccarone, D., Ondocsin, J., and Mars, S. G. (2017). Heroin uncertainties: exploring
users’ perceptions of fentanyl-adulterated and -substituted ’heroin’. Int. J. Drug
Policy 46, 146–155. doi: 10.1016/j.drugpo.2017.06.004
Coe, M. A., Pillitteri, J. L., Sembower, M. A., Gerlach, K. K., and Henningfield, J. E.
(2019). Kratom as a substitute for opioids: results from an online survey. Drug
Alcohol. Depend. 202, 24–32. doi: 10.1016/j.drugalcdep.2019.05.005
Coffeen, U., and Pellicer, F. (2019). Salvia divinorum: from recreational
hallucinogenic use to analgesic and anti-inflammatory action. J. Pain Res. 12,
1069–1076. doi: 10.2147/JPR.S188619
Concheiro, M., Chesser, R., Pardi, J., and Cooper, G. (2018). Postmortem toxicology
of new synthetic opioids. Front. Pharmacol. 9:1210. doi: 10.3389/fphar.2018.
01210
Corazza, O., Assi, S., Simonato, P., Corkery, J., Bersani, F. S., Demetrovics, Z., et al.
(2013). Promoting innovation and excellence to face the rapid diffusion of novel
psychoactive substances in the EU: the outcomes of the ReDNet project. Hum.
Psychopharmacol. 28, 317–323. doi: 10.1002/hup.2299
Corkery, J. M., Orsolini, L., Papanti, D., and Schifano, F. (2017). From concept(ion)
to life after death/the grave: the ’natural’ history and life cycle(s) of novel
psychoactive substances (NPS). Hum. Psychopharmacol. 32:3. doi: 10.1002/hup.
2566
Corkery, J. M., Orsolini, L., Papanti, D., and Schifano, F. (2018). Novel Psychoactive
Substances (NPS) and Recent Scenarios: Epidemiological, Anthropological and
Clinical Pharmacological Issues. Available online at: https://doi.org/10.1039/
9781788010344-00207 (accessed September 30, 2019).
Corkery, J. M., Streete, P., Claridge, H., Goodair, C., Papanti, D., Orsolini,
L., et al. (2019). Characteristics of deaths associated with kratom use.
J. Psychopharmacol. [Epub ahead of print].
Cunliffe, J., Décary-Hêtu, D., and Pollak, T. A. (2019). Nonmedical prescription
psychiatric drug use and the darknet: a cryptomarket analysis. Int. J. Drug Policy
[Epub ahead of print].
Davey, Z., Schifano, F., Corazza, O., Deluca, P., Schifano, F., Deluca, P.,
et al. (2012). e-Psychonauts: conducting research in online drug forum
communities. J. Ment. Health 21, 386–394. doi: 10.3109/09638237.2012.68
2265
Davies, M., Nowotka, M., Papadatos, G., Dedman, N., Gaulton, A., Atkinson, F.,
et al. (2015). ChEMBL web services: streamlining access to drug discovery data
and utilities. Nucleic Acids Res. 43, W612–W620. doi: 10.1093/nar/gkv352
DEA, (2019). Controlled Substances - Alphabetical Order. Available online
at: https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
(accessed August 22, 2019).
Deluca, P., Davey, Z., Corazza, O., Di Furia, L., Farre, M., Flesland, L. H.,
et al. (2012). Identifying emerging trends in recreational drug use; outcomes
from the Psychonaut Web Mapping Project. Prog. Neuropsychopharmacol. Biol.
Psychiatry 39, 221–226. doi: 10.1016/j.pnpbp.2012.07.011
D’Errico, S. (2018). Commentary. Fentanyl-related death and the underreporting
risk. J. Foren. Leg. Med. 60, 35–37. doi: 10.1016/j.jflm.2018.09.007
Drugs-forum (2007). Experiences - Ketobemidone Experiences. Available online
at: https://drugs-forum.com/threads/ketobemidone-experiences.128285/
(accessed August 28, 2019).
Ellis, C. R., Kruhlak, N. L., Kim, M. T., Hawkins, E. G., and Stavitskaya, L. (2018).
Predicting opioid receptor binding affinity of pharmacologically unclassified
designer substances using molecular docking. PLoS One 13:e0197734. doi: 10.
1371/journal.pone.0197734
Ellis, C. R., Racz, R., Kruhlak, N. L., Kim, M. T., Hawkins, E. G., Strauss,
D. G., et al. (2019). Assessing the structural and pharmacological similarity of
newly identified drugs of abuse to controlled substances using public health
assessment via structural evaluation. Clin. Pharmacol. Ther. 106, 116–122. doi:
10.1002/cpt.1418
EMBL-EBI (2019). CHEMBL Database Release 25. Available online at:
https://chembl.gitbook.io/chembl-interface-documentation/downloads
(accessed March 6, 2020).
Erowid (2015). Salvinorin B Ethoxymethyl Ether. Available online at:
https://erowid.org/chemicals/salvinorin_b_ethoxymethyl_ether/salvinorin_b_
ethoxymethyl_ether.shtml (accessed August 13, 2019).
European Database on New Drugs [EDND], (2019). EDND - Login Page. Available
online at: https://ednd2.emcdda.europa.eu/ednd/login (accessed August 28,
2019).
Frontiers in Neuroscience | www.frontiersin.org 7 March 2020 | Volume 14 | Article 149
fnins-14-00149 March 16, 2020 Time: 15:33 # 8
Arillotta et al. Novel Opioids and e-Psychonauts’ Scenario
European Monitoring Centre for Drugs and Drug Addiction [EMCDDA], (2019).
European Drug Report 2019. Available online at: http://www.emcdda.europa.eu/
edr2019 (accessed August 9, 2019).
Financial Crimes Enforcement Network [FinCHEN], (2019). Advisory to
Financial Institutions on Illicit Financial Schemes and Methods Related to
the Trafficking of Fentanyl and Other Synthetic Opioids. Available online at:
https://www.fincen.gov/sites/default/files/advisory/2019-08-21/Fentanyl%
20Advisory%20FINAL%20508.pdf (accessed January 3, 2019).
Fluyau, D., and Revadigar, N. (2017). Biochemical benefits, diagnosis, and clinical
risks evaluation of kratom. Front. Psychiatry 8:62. doi: 10.3389/fpsyt.2017.
00062
Frisoni, P., Bacchio, E., Bilel, S., Talarico, A., Gaudio, R. M., Barbieri, M., et al.
(2018). Novel synthetic opioids: the pathologist’s point of view. Brain Sci.
8:E170. doi: 10.3390/brainsci8090170
Galanie, S., Thodey, K., Trenchard, I. J., Filsinger Interrante, M., and Smolke,
C. D. (2015). Complete biosynthesis of opioids in yeast. Science 349, 1095–1100.
doi: 10.1126/science.aac9373
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D.,
et al. (2017). The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–D954.
doi: 10.1093/nar/gkw1074
Gerace, E., Salomone, A., Luciano, C., Di Corcia, D., and Vincenti, M. (2018a).
First Case in Italy of fatal intoxication involving the new opioid U-47700. Front.
Pharmacol. 9:747. doi: 10.3389/fphar.2018.00747
Gerace, E., Salomone, A., and Vincenti, M. (2018b). Analytical approaches in fatal
intoxication cases involving new synthetic opioids. Curr. Pharm. Biotechnol. 19,
113–123. doi: 10.2174/1389201019666180405162734
Gilardi, F., Augsburger, M., and Thomas, A. (2018). Will widespread synthetic
opioid consumption induce epigenetic consequences in future generations?
Front. Pharmacol. 9:702. doi: 10.3389/fphar.2018.00702
Giorgetti, A., Centola, C., and Giorgetti, R. (2017). Fentanyl novel derivative-
related deaths. Hum. Psychopharmacol. 32:3. doi: 10.1002/hup.2605
Google, (2019). Available online at: https://www.google.com/ (accessed September
30, 2019).
Google Scholar, (2019). Available online at: https://scholar.google.com/ (accessed
September 30, 2019).
GOV.UK, (2017). Controlled Drugs List. Available online at: https://www.gov.uk/
government/publications/controlled-drugs-list--2 (accessed August 22, 2019).
Graziano, S., Orsolini, L., Rotolo, M. C., Tittarelli, R., Schifano, F., and
Pichini, S. (2017). Herbal highs: review on psychoactive effects and
neuropharmacology. Curr. Neuropharmacol. 15, 750–761. doi: 10.2174/
1570159X14666161031144427
Guirguis, A., Corkery, J., Stair, J., Kirton, S., Zloh, M., and Schifano, F. (2017).
Intended and unintended use of cathinone mixtures. Hum. Psychopharmacol.
Clin. Exp. 32:e2598. doi: 10.1002/hup.2598
Hähnke, V. D., Kim, S., and Bolton, E. E. (2018). PubChem chemical structure
standardization. J. Cheminform. 10:36. doi: 10.1186/s13321-018-0293-8
Hassan, Z., Bosch, O. G., Singh, D., Narayanan, S., Kasinather, B. V.,
Seifritz, E., et al. (2017). Novel psychoactive substances-recent progress
on neuropharmacological mechanisms of action for selected drugs. Front.
Psychiatry 8:152. doi: 10.3389/fpsyt.2017.00152
Helmerhorst, G. T., Teunis, T., Janssen, S. J., and Ring, D. (2017). An epidemic
of the use, misuse and overdose of opioids and deaths due to overdose, in
the United States and Canada: is Europe next. Bone Joint J. 99, 856–864. doi:
10.1302/0301-620X.99B7.BJJ-2016-1350.R1
Huhn, A. S., Strain, E. C., Tompkins, D. A., and Dunn, K. E. (2018). A hidden
aspect of the U.S. opioid crisis: rise in first-time treatment admissions for
older adults with opioid use disorder. Drug Alcohol. Depend. 193, 142–147.
doi: 10.1016/j.drugalcdep.2018.10.002
International Narcotics Control Board [INCB], (2019a). INCB Fentanyl-
Related Substances With No Known Legitimate Uses. Available online
at: https://www.incb.org/incb/en/news/news_2019/experts-and-industry-
strategize-next-steps-in-implementing-incbs-list-of-fentanyl-related-
substances-with-no-legitimate-uses.html (accessed September 30, 2019).
International Narcotics Control Board [INCB], (2019b). INCB Yellow List. 2019.
Available online at: https://www.incb.org/incb/en/narcotic-drugs/Yellowlist_
Forms/yellow-list.html (accessed August 8, 2019).
Kacinko, S. L., and Papsun, D. M. (2019). The evolving landscape of designer drugs
methods. Mol. Biol. 1872, 129–135. doi: 10.1007/978-1-4939-8823-5_13
Kakko, J., Alho, H., Baldacchino, A., Molina, R., Nava, F. A., and Shaya, G. (2019).
Craving in opioid use disorder: from neurobiology to clinical practice. Front.
Psychiatry 10:592. doi: 10.3389/fpsyt.2019.00592
Kalyanam, J., Katsuki, T., Lanckriet, G., and Mackey, T. K. (2017). Exploring
trends of nonmedical use of prescription drugs and polydrug abuse in the
Twittersphere using unsupervised machine learning. Addict. Behav. 65, 289–
295. doi: 10.1016/j.addbeh.2016.08.019
Kata, V., Novitch, M. B., Jones, M. R., Anyama, B. O., Helander, E. M., and
Kaye, A. D. (2018). Opioid addiction, diversion, and abuse in chronic and
cancer pain. Curr. Opin. Support. Palliat. Care 12, 124–130. doi: 10.1097/SPC.
0000000000000333
Kelley-Quon, L. I., Cho, J., Strong, D. R., Miech, R. A., Barrington-Trimis, J. L.,
Kechter, A., et al. (2019). Association of nonmedical prescription opioid use
with subsequent heroin use initiation in adolescents. JAMA Pediatr. [Epub
ahead of print].
Kim, S. J., Marsch, L. A., Hancock, J. T., and Das, A. K. (2017). Scaling up research
on drug abuse and addiction through social media big data. J. Med. Internet Res.
19:e353. doi: 10.2196/jmir.6426
Kraemer, M., Boehmer, A., Madea, B., and Maas, A. (2019). Death cases involving
certain new psychoactive substances: a review of the literature. Foren. Sci. Int.
298, 186–267. doi: 10.1016/j.forsciint.2019.02.021
Krotulski, A. J., and Logan, B. K. (2018). Isopropyl-U-47700 Sample Type:
Biological Fluid. Available online at: https://www.forensicscienceeducation.
org/wp-content/uploads/2018/05/Isopropyl-U-47700_051818_
ToxicologyAnalyticalReport.pdf (accessed August 13, 2019).
Lajtai, A., Mayer, M., Lakatos, A., Porpáczy, Z., and Miseta, A. (2016).
Embutramide, a component of tanax( R©) (T-61) as a new drug of abuse. J. Foren.
Sci. 61, 573–575. doi: 10.1111/1556-4029.13010
Li, J., Xu, Q., Shah, N., and Mackey, T. K. (2019). A machine learning approach for
the detection and characterization of illicit drug dealers on instagram: model
evaluation study. J. Med. Internet Res. 21:e13803. doi: 10.2196/13803
Lipin´ski, P. F. J., Kosson, P., Matalin´ska, J., Roszkowski, P., Czarnocki, Z.,
Jaron´czyk, M., et al. (2019). Fentanyl family at the mu-opioid receptor: uniform
assessment of binding and computational analysis. Molecules 24:E740. doi: 10.
3390/substances24040740
Liu, Z., and Udenigwe, C. C. (2018). Role of food-derived opioid peptides in
the central nervous and gastrointestinal systems. J. Food Biochem. 43:e12629.
doi: 10.1111/jfbc.12629
Loi, B., Zloh, M., De Luca, M. A., Pintori, N., Corkery, J., and Schifano, F. (2017).
4,4′-Dimethylaminorex (‘4,4′-DMAR’; Serotoni’) misuse: a web-based study.
Hum. Psychopharmacol. Clin. Exp. 32:E2575. doi: 10.1002/hup.2575
Lovrecic, B., Lovrecic, M., Gabrovec, B., Carli, M., Pacini, M., Maremmani, A. G. I.,
et al. (2019). Non-medical use of novel synthetic opioids: a new challenge
to public health. Int. J. Environ. Res. Public Health 16:E177. doi: 10.3390/
ijerph16020177
Mackey, T., Kalyanam, J., Klugman, J., Kuzmenko, E., and Gupta, R. (2018).
Solution to detect, classify, and report illicit online marketing and sales of
controlled substances via twitter: using machine learning and web forensics
to combat digital opioid access. J. Med. Internet Res. 20:e10029. doi: 10.2196/
10029
McLean, K., Monnat, S. M., Rigg, K., Sterner, G. E., and Verdery, A. (2019).
You never know what you’re getting: opioid users’ perceptions of fentanyl in
southwest pennsylvania. Subst. Use Misuse 54, 955–966. doi: 10.1080/10826084.
2018.1552303
Misailidi, N., Papoutsis, I., Nikolaou, P., Dona, A., Spiliopoulou, C., and
Athanaselis, S. (2018). Fentanyls continue to replace heroin in the drug arena:
the cases of ocfentanil and carfentanil. Foren. Toxicol. 36, 12–32. doi: 10.1007/
s11419-017-0379-4
Morrow, J. B., Ropero-Miller, J. D., Catlin, M. L., Winokur, A. D., Cadwallader,
A. B., Staymates, J. L., et al. (2019). The opioid epidemic: moving toward an
integrated, holistic analytical response. J. Anal. Toxicol. 43, 1–9. doi: 10.1093/
jat/bky049
Negri, L., Melchiorri, P., and Lattanzi, R. (2000). Pharmacology of amphibian
opiate peptides. Peptides 21, 1639–1647. doi: 10.1016/s0196-9781(00)00
295-3
Ohinata, K., Agui, S., and Yoshikawa, M. (2007). Soymorphins, novel mu opioid
peptides derived from soy beta-conglycinin beta-subunit, have anxiolytic
activities. Biosci. Biotechnol. Biochem. 71, 2618–2621. doi: 10.1271/bbb.70516
Frontiers in Neuroscience | www.frontiersin.org 8 March 2020 | Volume 14 | Article 149
fnins-14-00149 March 16, 2020 Time: 15:33 # 9
Arillotta et al. Novel Opioids and e-Psychonauts’ Scenario
Orsolini, L., Papanti, D., Corkery, J., and Schifano, F. (2017). An insight into the
deep web; why it matters for addiction psychiatry. Hum. Psychopharmacol. 32,
e2573. doi: 10.1002/hup.2573
Orsolini, L., Papanti, G. D., Francesconi, G., and Schifano, F. (2015).
Mind navigators of chemicals’ experimenters? A web-based description of
e-psychonauts. Cyberpsychol. Behav. Soc. Netw. 18, 296–300. doi: 10.1089/cyber.
2014.0486
Oye, K. A., Lawson, J. C., and Bubela, T. (2015). Drugs: regulate ’home-brew’
opiates. Nature 521, 281–283. doi: 10.1038/521281
Pandrekar, S., Chen, X., Gopalkrishna, G., Srivastava, A., Saltz, M., Saltz, J., et al.
(2018). Social media based analysis of opioid epidemic using reddit AMIA.
Annu. Symp. Proc. 2018, 867–876.
Pardo, B., Taylor, J., Caulkins, J. P., Kilmer, B., Reuter, P., and Stein,
B. D. (2019). The Future of Fentanyl and Other Synthetic Opioids.
Available online at: https://www.rand.org/content/dam/rand/pubs/research_
reports/RR3100/RR3117/RAND_RR3117.pdf (accessed January 3, 2019).
Peet, M. M., and Baker, L. E. (2011). Salvinorin B derivatives, EOM-Sal B and
MOM-Sal B, produce stimulus generalization in male sprague-dawley rats
trained to discriminate salvinorin A. Behav. Pharmacol. 22, 450–457. doi: 10.
1097/FBP.0b013e328349fc1b
Pérez-Mañá, C., Papaseit, E., Fonseca, F., Farré, A., Torrens, M., and Farré, M.
(2018). Drug interactions with new synthetic opioids. Front. Pharmacol. 9:1145.
doi: 10.3389/fphar.2018.01145
Pergolizzi, J. V. Jr., Raffa, R. B., Taylor, R. Jr., and Vacalis, S. (2018). Abuse-deterrent
opioids: an update on current approaches and considerations. Curr. Med. Res.
Opin. 34, 711–723. doi: 10.1080/03007995.2017
Pichini, S., Solimini, R., Berretta, P., Pacifici, R., and Busardò, F. P. (2018). Acute
intoxications and fatalities from illicit fentanyl and analogues: an update. Ther.
Drug Monit. 40, 38–51. doi: 10.1097/FTD.0000000000000465
PiHKAL, (2019). Fentanyl Landscape Info. Available online at: https:
//isomerdesign.com/PiHKAL/tableLandscape.php?domain=pk&property=
fentanyl&sort=name (accessed August 8, 2019).
Prekupec, M. P., Mansky, P. A., and Baumann, M. H. (2017). Misuse of novel
synthetic opioids: a deadly new trend. J. Addict. Med. 11, 256–265. doi: 10.1097/
ADM.0000000000000324
PubChem, (2019). Available online at: https://pubchem.ncbi.nlm.nih.gov/
(accessed August 8, 2019).
PubMed, (2019). Home - PubMed - NCBI. Available online at: https://www.ncbi.
nlm.nih.gov/pubmed/ (accessed September 30, 2019).
Reddit, (2019a). Bromadol BDPC?: Researchchemicals. Available online at: https:
//www.reddit.com/r/researchchemicals/comments/an9mos/bromadol_bdpc/
(accessed August 13, 2019).
Reddit, (2019b). Human Bioassay of Salvinorin B Ethoxymethyl Ether (Symmetry)
a Novel and Unusually Potent and Longer Lasting Salvinorin Analogue:
Salvia. Available online at: https://www.reddit.com/r/Salvia/comments/42j4ew/
human_bioassay_of_salvinorin_b_ethoxymethyl_ether/ (accessed August 13,
2019).
Reddit, (2019c). Ketobemidone Derivates - Considered One of the Holy
Grail of Opiates, since They Are Not Even Scheduled, Why They
Don’t Hit the RCs Scene Markets?: Opioid_RCs. Available online at:
https://www.reddit.com/r/Opioid_RCs/comments/bbdwlv/ketobemidone_
derivates_considered_one_of_the_holy/ (accessed August 28, 2019).
Reddit, (2019d). Opiates. Available online at: https://www.reddit.com/r/opiates/
(accessed August 28, 2019).
Reddit, (2019e). Other than Fent, What Are Other Cutting Chems?: Opiates.
Available online at: https://www.reddit.com/r/opiates/comments/bq2k4s/
other_than_fent_what_are_other_cutting_chems/ (accessed August 13, 2019).
Reddit, (2019f). Salvinorin B Methoxymethyl Ether: A Drug For Brave
Psychonauts?: Researchchemicals. Available online at: https://www.reddit.
com/r/researchchemicals/comments/8fm9p4/salvinorin_b_methoxymethyl_
ether_a_drug_for_brave/ (accessed August 28, 2019).
Schifano, F., Chiappini, S., Corkery, J. M., and Guirguis, A. (2019a). Assessing
the 2004-2018 fentanyl misusing issues reported to an international range of
adverse reporting systems. Front. Pharmacol. 10:46. doi: 10.3389/fphar.2019.
00046
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso,
S., et al. (2019b). New/emerging psychoactive substances and associated
psychopathological consequences. Psychol. Med. [Epub ahead of print].
Schifano, F., Orsolini, L., Duccio Papanti, G., and Corkery, J. M. (2015). Novel
psychoactive substances of interest for psychiatry. World Psychiatry 14, 15–26.
doi: 10.1002/wps.20174
Schueler, H. E. (2017). Emerging synthetic fentanyl analogs. Acad. Foren. Pathol. 7,
36–40. doi: 10.23907/2017.004
Sharma, K. K., Hales, T. G., Rao, V. J., NicDaeid, N., and McKenzie, C. (2019). The
search for the "next" euphoric non-fentanil novel synthetic opioids on the illicit
drugs market: current status and horizon scanning. Foren. Toxicol. 37, 1–16.
doi: 10.1007/s11419-018-0454-5
Simonato, P., Corazza, O., Santonastaso, P., Corkery, J., Deluca, P., Davey, Z.,
et al. (2013). Novel psychoactive substances as a novel challenge for health
professionals: results from an Italian survey. Hum. Psychopharmacol. 28, 324–
331. doi: 10.1002/hup.2300
Smith, J. S., Lefkowitz, R. J., and Rajagopal, S. (2018). Biased signalling: from simple
switches to allosteric microprocessors. Nat. Rev. Drug Discov. 17, 243–260.
doi: 10.1038/nrd.2017.229
Stein, C. (2016). Opioid receptors. Annu. Rev. Med. 67, 433–451. doi: 10.1146/
annurev-med-062613-093100
Stein, M. D., Kenney, S. R., Anderson, B. J., and Bailey, G. L. (2019). Perceptions
about fentanyl-adulterated heroin and overdose risk reduction behaviors
among persons seeking treatment for heroin use. J. Subst. Abuse Treat. 104,
144–147. doi: 10.1016/j.jsat.2019.07.006
Suzuki, J., and El-Haddad, S. (2017). A review: fentanyl and non-pharmaceutical
fentanyls. Drug Alcohol. Depend. 171, 107–116. doi: 10.1016/j.drugalcdep.2016.
11.033
Tabarra, I., Soares, S., Rosado, T., Gonçalves, J., Luís, A., Malaca, S., et al. (2019).
Novel synthetic opioids - toxicological aspects and analysis. Foren. Sci. Res. 4,
111–140. doi: 10.1080/20961790.2019.1588933
Teschemacher, H., Koch, G., and Brantl, V. (1997). Milk protein-derived opioid
receptor ligands. Biopolymers 43, 99–117. doi: 10.1002/(sici)1097-0282(1997)
43:2<99::aid-bip3>3.0.co;2-v
TripSit Factsheets, (2019a). Bromadol. Available online at: http://drugs.tripsit.me/
bromadol (accessed August 13, 2019).
TripSit Factsheets, (2019b). 6-MDDM. Available online at: http://drugs.tripsit.me/
6-mddm (accessed August 13, 2019).
Tzanetakis, M. (2018). Comparing cryptomarkets for drugs. A characterisation of
sellers and buyers over time. Int. J. Drug Policy 56, 176–186. doi: 10.1016/j.
drugpo.2018.01.022
United Nations Office on Drugs and Crime [UNODC], (1954). UNODC - Bulletin
on Narcotics - 1954 Issue 3 - 005. Available online at: https://www.unodc.org/
unodc/en/data-and-analysis/bulletin/bulletin_1954-01-01_3_page006.html
(accessed August 28, 2019).
United Nations Office on Drugs and Crime [UNODC], (2019a). Conventions.
Available online at: https://www.unodc.org/unodc/en/commissions/CND/
conventions.html (accessed August 12, 2019).
United Nations Office on Drugs and Crime [UNODC], (2019b). UNODC Early
Warning Advisory (EWA) on New Psychoactive Substances (NPS). Available
online at: https://www.unodc.org/LSS/Home/NPS (accessed August 8, 2019).
United Nations Office on Drugs and Crime [UNODC], (2019c). World
Drug Report 2019: 35 Million People Worldwide Suffer from Drug Use
Disorders While Only 1 in 7 People Receive Treatment. Available online at:
https://www.unodc.org/unodc/en/frontpage/2019/June/world-drug-report-
2019_-35-million-people-worldwide-suffer-from-drug-use-disorders-while-
only-1-in-7-people-receive-treatment.html (accessed August 9, 2019).
Unodc Early Warning Advisory on New Psychoactive Substances [UNODC
EWA NPS], (2019). News: February 2019 – UNODC-SMART: Almost 900
NPS Reported to UNODC from 119 Countries and Territories. Available
online at: https://www.unodc.org/LSS/Announcement/Details/eff8dc38-7ab0-
42b0-8cd9-753b89953fcc (accessed September 30, 2019).
Valentino, R. J., and Volkow, N. (2018). Untangling the complexity of opioid
receptor function. Neuropsychopharmacology 43, 2514–2520. doi: 10.1038/
s41386-018-0225-3
van Amsterdam, J., and van den Brink, W. (2015). The misuse of prescription
opioids: a threat for europe. Curr. Drug Abuse Rev. 8, 3–14. doi: 10.2174/
187447370801150611184218
Varga, A. G., Reid, B. T., Kieffer, B. L., and Levitt, E. S. (2020). Differential impact
of two critical respiratory centres in opioid-induced respiratory depression in
awake mice. J. Physiol. 598, 189–205. doi: 10.1113/JP278612
Frontiers in Neuroscience | www.frontiersin.org 9 March 2020 | Volume 14 | Article 149
fnins-14-00149 March 16, 2020 Time: 15:33 # 10
Arillotta et al. Novel Opioids and e-Psychonauts’ Scenario
Ventura, L., Carvalho, F., and Dinis-Oliveira, R. J. (2018). Opioids in the
frame of new psychoactive substances network: a complex pharmacological
and toxicological issue. Curr. Mol. Pharmacol. 11, 97–108. doi: 10.2174/
1874467210666170704110146
Wang, Y. S. (2019). Exploring the "like" in the psychological interaction of users on
fan community: a netnography analysis. J. Commun. Psychol. 47, 1380–1398.
doi: 10.1002/jcop.22192
Whitehouse, (2019). 21st Century Drug Trafficking: “Manufacturing Advisory”
on Fentanyl and Other Synthetic Opioids (Tab A). Available online
at: https://www.whitehouse.gov/wp-content/uploads/2019/08/Fentanyl-
Advisory-Manufacturing-Tab-A.pdf (accessed January 3, 2020).
WHO Collaborating Centre [WHOCC], (2016). WHOCC - ATC Classification
of Combinations of Opioids and Other Analgesics. Available online at:
https://www.whocc.no/news/atc_classification_of_combinations_of_opioids_
and_other_anal (accessed July 18, 2019).
WHO Collaborating Centre [WHOCC], (2019). WHOCC - ATC/DDD Index.
Available online at: https://www.whocc.no/atc_ddd_index/ (accessed August 9,
2019).
Wilcoxon, R. M., Middleton, O. L., Meyers, S. E., Kloss, J., and Love, S. A. (2018).
The elephant in the room: outbreak of carfentanil deaths in minnesota and
the importance of multiagency collaboration. Acad. Foren. Pathol. 8, 729–737.
doi: 10.1177/1925362118797746
Wilde, M., Pichini, S., Pacifici, R., Tagliabracci, A., Busardò, F. P., Auwärter, V.,
et al. (2019). Metabolic pathways and potencies of new fentanyl analogs. Front.
Pharmacol. 10:238. doi: 10.3389/fphar.2019.00238
World Health Organization [WHO], (2016). U-47700 Critical Review Report
Agenda Item 4.1 Expert Committee on Drug Dependence Thirty-Eighth Meeting.
Available online at: https://www.who.int/medicines/access/controlled-
substances/4.1_U-47700_CritReview.pdf (accessed August 12, 2019).
World Health Organization [WHO], (2018). WHO Expert Committee
on Drug Dependence Forty-First Report. Available online at: https:
//www.who.int/medicines/access/controlled-substances/ecdd_41_meeting/en/
(accessed August 12, 2019).
Xu, H., Chen, J., and Chi, Z. Q. (1985). Ohmefentanyl–a new agonist for mu-opiate
receptor. Chem. Biol. Agric. Med. Earth Sci. 28, 504–511.
Yin, S. (2019). Adolescents and drug abuse: 21st century synthetic substances. Clin.
Pediatr. Emerg. Med. 20, 17–24. doi: 10.1016/J.CPEM.2019.03.003
Zawilska, J. B. (2017). An expanding world of novel psychoactive substances:
opioids. Front. Psychiatr. 8:110. doi: 10.3389/fpsyt.2017.00110
Zhao, M. (2019). The illicit supply of new psychoactive substances within and from
china: a descriptive analysis. Int. J. Offend. Ther. Comp. Crim. [Epub ahead of
print].
Zjawiony, J. K., Machado, A. S., Menegatti, R., Ghedini, P. C., Costa, E. A.,
Pedrino, G. R., et al. (2019). Cutting-edge search for safer opioid pain relief:
retrospective review of salvinorin a and its analogs. Front. Psychiatry 10:157.
doi: 10.3389/fpsyt.2019.00157
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Arillotta, Schifano, Napoletano, Zangani, Gilgar, Guirguis,
Corkery, Aguglia and Vento. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 10 March 2020 | Volume 14 | Article 149
